← All trials
NCT07007637
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 27, 2025
- Primary completion
- Jun 13, 2028
- Completion date
- Jun 13, 2028
- First posted
- Jun 6, 2025
- Last posted
- Sep 30, 2025
- Enrollment
- 835
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- MoonLake Immunotherapeutics AGLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.